<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149679_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152624</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012IT106893</safetyreportid>
		<primarysourcecountry>IT</primarysourcecountry>
		<occurcountry>IT</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>1</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121119</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130121</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012IT106893</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>182052</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>CM</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19290418</patientbirthdate>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Glucose-6-phosphate dehydrogenase deficiency</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Arthralgia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Arthralgia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Arthralgia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Asthenia strong</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Asthenia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Asthenia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Heartburn</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Heartburn</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyspepsia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Epigastric pain</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Epigastric pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Abdominal pain upper</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Edema</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Edema</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Oedema</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Azotemia 126 (unknown)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Azotemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Azotaemia</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Blood urea 38 (units unknown)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Blood urea decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood urea decreased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121105</reactionstartdate>
				<reactionfirsttime>138</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>41</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hemoglobin 8/ hemoglobin 10 (unk units)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hemoglobin low</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Haemoglobin decreased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Creatinine 2,4 (units unknown)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Creatinine high</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood creatinine increased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120926</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121105</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121105</testdate>
				<testname>Blood potassium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121105</testdate>
				<testname>Blood urea</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120926</testdate>
				<testname>Haemoglobin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121105</testdate>
				<testname>Haemoglobin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>RASILEZ</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationnumb>21-985</drugauthorizationnumb>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>150</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugcumulativedosagenumb>150</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>150 mg, daily</drugdosagetext>
				<drugdosageform>Coated tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120621</drugstartdate>
				<drugstartperiod>98</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120926</drugenddate>
				<drugtreatmentduration>98</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>1</actiondrug>
				<activesubstance>
					<activesubstancename>ALISKIREN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain upper</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain upper</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Arthralgia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Arthralgia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Asthenia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Asthenia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Azotaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Azotaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood urea decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood urea decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspepsia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspepsia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemoglobin decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemoglobin decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>MEDIPO</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>20</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>20 mg, UNK</drugdosagetext>
				<drugdosageform>Coated tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120921</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120926</drugenddate>
				<drugtreatmentduration>6</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>SIMVASTATIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>DIURESIX</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>10 mg, UNK</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120702</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120926</drugenddate>
				<drugtreatmentduration>87</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TORASEMIDE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CORDARONE</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>200</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>200 mg, UNK</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120618</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120926</drugenddate>
				<drugtreatmentduration>101</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMIODARONE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>IPERTEN</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>20</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>20 mg, UNK</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20030702</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120926</drugenddate>
				<drugtreatmentduration>3375</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MANIDIPINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ZYLORIC</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>150</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>150 mg</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20111120</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120926</drugenddate>
				<drugtreatmentduration>312</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ALLOPURINOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LANSOX</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>15</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>15 mg, UNK</drugdosagetext>
				<drugdosageform>Hard-Gelatin Capsule</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20050901</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120926</drugenddate>
				<drugtreatmentduration>2583</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LANSOPRAZOLE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CARDIOASPIRIN</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>100 mg, UNK</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120313</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20120926</drugenddate>
				<drugtreatmentduration>198</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ACETYLSALICYLIC ACID</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012IT106893, is an initial spontaneous report from a health care professional via Health Authority (182052) received on 19 Nov 2012, with follow-up report received from a health care professional via Health Authority (182052) on 21 Jan 2013. This report refers to an 83-year-old female patient. The patient's medical history included concurrent condition G-6 PD deficiency (Glucose-6-phosphate dehydrogenase deficiency). Concomitant medications included Medipo (simvastatin) 20 mg coated tablets, orally from 21 Jun 2012, Diuresix (torasemide) 10 mg tablets, orally from 02 Jul 2012, Cardarone (amiodarone) 200 mg tablets orally from 18 Jun 2012, Iperten (manidipine) 20 mg tablets orally from 02 Jul 2003, Zyloric (allopurinol) 300 mg tablets, at a dose of 150 mg orally from 20 Oct 2011, Lansox (lansoprazole) 15 mg hard capsules orally from 01 Sep 2005 and Cardioaspirin (acetyl salicylic acid) 100 mg tablets, orally from 13 Mar 2012, all for unknown indication and stopped on 26 Sep 2012. The patient received Rasilez (aliskiren) 150 mg coated tablets daily, orally for the treatment of hypertension from 21 Jun 2012. On 26 Sep 2012, the patient experienced arthralgia, asthenia strong, edema, heartburn and epigastric pain. On 26 Sep 2012, laboratory test showed hemoglobin was 8, azotemia 126, creatinine 2.4, azotemia 126 and potassium 6 (units and normal values not provided). On 05 Nov 2012, laboratory test showed hemoglobin was 10, blood urea 38, creatinine 1.5, azotemia 38 and potassium 5 (units not specified). Treatment with Rasilez was discontinued on 26 Sep 2012. The outcome of the events arthralgia, asthenia strong, edema, heartburn and epigastric pain was condition recovered after discontinuation of suspect drug, the seriousness was reported as disability (serious) and causality related to treatment with Rasilez. The outcome, seriousness and causality of rest of events were not reported. 

Follow-up report received from a health care professional on 21 Jan 2013: Events (Hemoglobin 8/ 10, Creatinine 2,4, azotemia 126 and Blood urea 38 ) added. Lab data updated. Narrative updated.</narrativeincludeclinical>
				<sendercomment>Underlying age and G 6 PD defficieny could be the confounders, however available information precludes a proper causality assessment. The events are unassessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
